Marina R Piper1, D Michal Freedman1, Kim Robien1, William Kopp1, Helen Rager1, Ronald L Horst1, Rachael Z Stolzenberg-Solomon2. 1. From the Nutritional Epidemiology Branch (MRP and RZS-S) and the Radiation Epidemiology Branch (DMF), Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; the Departments of Epidemiology and Biostatistics and Exercise Science, Milken Institute School of Public Health, George Washington University, Washington, DC (KR); the Clinical Support Laboratory, Leidos Biomedical Research Inc./Frederick National Laboratory for Cancer Research, Frederick, MD (WK and HR); and Heartland Assays Inc., Iowa State University, Ames, IA (RLH). 2. From the Nutritional Epidemiology Branch (MRP and RZS-S) and the Radiation Epidemiology Branch (DMF), Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; the Departments of Epidemiology and Biostatistics and Exercise Science, Milken Institute School of Public Health, George Washington University, Washington, DC (KR); the Clinical Support Laboratory, Leidos Biomedical Research Inc./Frederick National Laboratory for Cancer Research, Frederick, MD (WK and HR); and Heartland Assays Inc., Iowa State University, Ames, IA (RLH). rs221z@nih.gov.
Abstract
BACKGROUND: Vitamin D-binding protein (DBP) is the primary carrier of 25-hydroxyvitamin D [25(OH)D] in the circulation. One prospective study in male smokers found a protective association between DBP and pancreatic cancer, particularly among men with higher 25(OH)D concentrations. OBJECTIVE: The objective was to examine the association between DBP and pancreatic cancer risk in an American population. DESIGN: We conducted a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer screening trial cohort of men and women aged 55-74 y at baseline. Between 1993 and 2010, 295 incident pancreatic adenocarcinoma cases were reported (follow-up to 15.1 y). Two controls (n = 590) were matched to each case by age, race, sex, and month of blood draw. We calculated smoking- and diabetes-adjusted ORs and 95% CIs with the use of conditional logistic regression. RESULTS: DBP concentration was not significantly associated with pancreatic cancer overall [highest (≥7149.4 nmol/L) vs. lowest (<3670.4 nmol/L) quintile; OR: 1.75; 95% CI: 0.91, 3.37; P-trend = 0.25]. For serum 25(OH)D compared with the referent (50 to <75 nmol/L), individuals in the highest group had a significantly higher risk (≥100 nmol/L; OR: 3.23; 95% CI: 1.24, 8.44), whereas those in the lowest group had no significant association (<25 nmol/L; OR: 2.50; 95% CI: 0.92, 6.81). Further adjustment for DBP did not alter this association. CONCLUSION: Our results do not support the hypothesis that serum DBP or 25(OH)D plays a protective role in pancreatic cancer. This trial was registered at clinicaltrials.gov as NCT00339495.
BACKGROUND:Vitamin D-binding protein (DBP) is the primary carrier of 25-hydroxyvitamin D [25(OH)D] in the circulation. One prospective study in male smokers found a protective association between DBP and pancreatic cancer, particularly among men with higher 25(OH)D concentrations. OBJECTIVE: The objective was to examine the association between DBP and pancreatic cancer risk in an American population. DESIGN: We conducted a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer screening trial cohort of men and women aged 55-74 y at baseline. Between 1993 and 2010, 295 incident pancreatic adenocarcinoma cases were reported (follow-up to 15.1 y). Two controls (n = 590) were matched to each case by age, race, sex, and month of blood draw. We calculated smoking- and diabetes-adjusted ORs and 95% CIs with the use of conditional logistic regression. RESULTS:DBP concentration was not significantly associated with pancreatic cancer overall [highest (≥7149.4 nmol/L) vs. lowest (<3670.4 nmol/L) quintile; OR: 1.75; 95% CI: 0.91, 3.37; P-trend = 0.25]. For serum 25(OH)D compared with the referent (50 to <75 nmol/L), individuals in the highest group had a significantly higher risk (≥100 nmol/L; OR: 3.23; 95% CI: 1.24, 8.44), whereas those in the lowest group had no significant association (<25 nmol/L; OR: 2.50; 95% CI: 0.92, 6.81). Further adjustment for DBP did not alter this association. CONCLUSION: Our results do not support the hypothesis that serum DBP or 25(OH)D plays a protective role in pancreatic cancer. This trial was registered at clinicaltrials.gov as NCT00339495.
Authors: F F Safadi; P Thornton; H Magiera; B W Hollis; M Gentile; J G Haddad; S A Liebhaber; N E Cooke Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: Richard B Hayes; Alice Sigurdson; Lee Moore; Ulrike Peters; Wen-Yi Huang; Paul Pinsky; Douglas Reding; Edward P Gelmann; Nat Rothman; Ruth M Pfeiffer; Robert N Hoover; Christine D Berg Journal: Mutat Res Date: 2005-07-27 Impact factor: 2.433
Authors: Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-07 Impact factor: 4.254
Authors: Gary G Schwartz; Dawn Eads; Anuradha Rao; Scott D Cramer; Mark C Willingham; Tai C Chen; Daniel P Jamieson; Lilin Wang; Kerry L Burnstein; Michael F Holick; Constantinos Koumenis Journal: Carcinogenesis Date: 2004-01-23 Impact factor: 4.944
Authors: Kasper A Overbeek; Djuna L Cahen; Marcia Irene Canto; Marco J Bruno Journal: Best Pract Res Clin Gastroenterol Date: 2016-11-05 Impact factor: 3.043
Authors: Fränzel J B van Duijnhoven; Mazda Jenab; Kristian Hveem; Peter D Siersema; Veronika Fedirko; Eric J Duell; Ellen Kampman; Anouk Halfweeg; Henk J van Kranen; Jody M W van den Ouweland; Elisabete Weiderpass; Neil Murphy; Arnulf Langhammer; Eivind Ness-Jensen; Anja Olsen; Anne Tjønneland; Kim Overvad; Claire Cadeau; Marina Kvaskoff; Marie-Christine Boutron-Ruault; Verena A Katzke; Tilman Kühn; Heiner Boeing; Antonia Trichopoulou; Anastasia Kotanidou; Maria Kritikou; Domenico Palli; Claudia Agnoli; Rosario Tumino; Salvatore Panico; Giuseppe Matullo; Petra Peeters; Magritt Brustad; Karina Standahl Olsen; Cristina Lasheras; Mireia Obón-Santacana; María-José Sánchez; Miren Dorronsoro; Maria-Dolores Chirlaque; Aurelio Barricarte; Jonas Manjer; Martin Almquist; Frida Renström; Weimin Ye; Nick Wareham; Kay-Tee Khaw; Kathryn E Bradbury; Heinz Freisling; Dagfinn Aune; Teresa Norat; Elio Riboli; H B As Bueno-de-Mesquita Journal: Int J Cancer Date: 2017-11-22 Impact factor: 7.396